AACR19: rucaparib produces clinical response in certain pancreatic cancer patients

Credit: Min Yu (Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC) Maintenance therapy with the PARP inhibitor rucaparib (Rubraca®) has produced clinical responses amongst a subgroup of patients with advanced BRCA- or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy.Results of the Phase II clinical trial highlight the importance of germline and somatic testing to guide treatment in pancreatic cancer patients. “In this interim analysis, we are finding that patients with platinum-sensitive pancreatic cancer appear to benefit from treatment with single agent rucaparib,” commented Kim Reiss Binder, The University of Pennsylvania (PA, USA). “Several patients had...